(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 10.33%
Live Chart Being Loaded With Signals
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States...
Stats | |
---|---|
今日成交量 | 254 478 |
平均成交量 | 248 485 |
市值 | 84.64M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.91 |
ATR14 | $0.0190 (1.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Brown Scott B. | Buy | 224 800 | Employee Stock Option (Right to Buy) |
2023-04-20 | Brown Scott B. | Buy | 3 500 | Common Stock |
2024-03-12 | Theuer Charles | Buy | 518 300 | Employee Stock Option (Right to Buy) |
2023-10-20 | Theuer Charles | Buy | 3 500 | Common Stock |
2023-04-20 | Theuer Charles | Buy | 3 500 | Common Stock |
INSIDER POWER |
---|
80.91 |
Last 100 transactions |
Buy: 3 843 498 | Sell: 406 947 |
音量 相关性
TRACON Pharmaceuticals 相关性 - 货币/商品
TRACON Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $12.05M |
毛利润: | $12.03M (99.88 %) |
EPS: | $-0.110 |
FY | 2023 |
营收: | $12.05M |
毛利润: | $12.03M (99.88 %) |
EPS: | $-0.110 |
FY | 2022 |
营收: | $0 |
毛利润: | $-16 000.00 (0.00 %) |
EPS: | $-1.400 |
FY | 2021 |
营收: | $346 000 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.660 |
Financial Reports:
No articles found.
TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。